<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210973</url>
  </required_header>
  <id_info>
    <org_study_id>AYPB-MDD-Ⅲ-201901</org_study_id>
    <secondary_id>2018ZX09734-005</secondary_id>
    <nct_id>NCT04210973</nct_id>
  </id_info>
  <brief_title>Comparison of Anyu Peibo With Placebo in Treatment of MDD in China</brief_title>
  <official_title>Efficacy and Safety Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Ⅲ Randomized, Double-Blind, Placebo-Paralleled, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Su Zhou YiHua Biotechnology Co. LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Anyu Peibo Capsule
      comparing with placebo in the treatment of Chinese Patients with Depression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of total score from baseline in Montgomery Asberg Depression Rating Scale （MADRS）</measure>
    <time_frame>8 weeks</time_frame>
    <description>the minimum and maximum values of MADRS are from 0 to 60, and higher scores mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission Rate according to total score of MADRS at the end of study</measure>
    <time_frame>8 weeks</time_frame>
    <description>Remission=at the end of study, total score of MADRS ≤10, the minimum and maximum values of MADRS are from 0 to 60, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission Rate according to 17-items Hamilton Depression Scale (HAMD17) total score at the end of study</measure>
    <time_frame>8 weeks</time_frame>
    <description>Remission=at the end of study, total score of HAMD17 ≤7, the minimum and maximum values of HAMD17 are from 0 to 52, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total score of MADRS by time</measure>
    <time_frame>8 weeks</time_frame>
    <description>the minimum and maximum values of MADRS are from 0 to 60, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total score from baseline in HAMD17</measure>
    <time_frame>8 weeks</time_frame>
    <description>the minimum and maximum values of HAMD17 are from 0 to 52, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total score from baseline in Hamilton Anxiety Scale (HAMA)</measure>
    <time_frame>8 weeks</time_frame>
    <description>the minimum and maximum values of HAMA are from 0 to 56, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of score from baseline in Clinical Global Impression-Severity of Illness (CGI-S)</measure>
    <time_frame>8 weeks</time_frame>
    <description>the minimum and maximum values of CGI-S are from 1 to 7, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Severity of Illness (CGI-I) score</measure>
    <time_frame>8 weeks</time_frame>
    <description>the minimum and maximum values of CGI-I are from 1 to 7, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total score from baseline in Discriminative Scale Space Tracker (DSST)</measure>
    <time_frame>8 weeks</time_frame>
    <description>the minimum and maximum values of DSST are from 0 to 90, and higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total score from baseline in Trail Making Test (TMT) A&amp;B</measure>
    <time_frame>8 weeks</time_frame>
    <description>the minimum and maximum values of TMT are from 0 to 300, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total score from baseline in Sheehan Disability Scale (SDS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>the minimum and maximum values of SDS are from 0 to 10, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who withdrew from clinical trial due to poor efficacy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Investigator will assess subject's efficacy according to his/her clinical status with rating scales, including MADRS, HAMD17, HAMA and CGI, which already listed in Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who combined medication to treat insomnia</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of AE</measure>
    <time_frame>8 weeks</time_frame>
    <description>AE=Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>per minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>per minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heartbeat Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>per minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Sitting position, mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Sitting position, mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram(ECG)</measure>
    <time_frame>8 weeks</time_frame>
    <description>the number of subjects with abnormal ECG report by 12-lead electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Arizona Sexual Experience Scale (ASES)</measure>
    <time_frame>8 weeks</time_frame>
    <description>the minimum and maximum values of ASES are from 1 to 6, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with AE result in early withdrawal from clinical trials</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious Adverse Event (SAE) result in early withdrawal from clinical trials</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Emerging AE during drug withdrawal period</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Anyu Peibo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anyu Peibo Capsule, oral, 0.8g twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo,oral, twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anyu Peibo</intervention_name>
    <description>Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper</description>
    <arm_group_label>Anyu Peibo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Capsule, twice per day, oral after breakfast and supper</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult with primary diagnosis of major depressive disorder(MDD) based on the criteria
             of DSM-5, single episode or recurrent episode. [296.21; 296.22; 296.23; 296.31;
             296.32; 296.33]

          -  The total score of MADRS is ≥26 in both screening visit and baseline visit.

          -  The first item of MADRS is ≥3 in both screening visit and baseline visit.

          -  CGI-S is ≥4 in both screening visit and baseline visit.

          -  The subject understands and consents to takes part in this clinical trials. The
             subjects should sign informed consent form.

        Exclusion Criteria:

          -  The subject has a current psychiatric diagnosis other than depression.

          -  The subject has a suicide attempt within recent 1 year, or has a currently significant
             risk of suicide, or has a score ≥3 on item 10 (suicidal ideation) of MADRS.

          -  The subject has a current depressive episode due to somatic general disease or a
             neurological disease, such as hypothyroidism.

          -  When the MADRS total score of baseline visit compares with the screening visit, the
             decreasing rate is ≥25%.

          -  Known hypersensitivity to Big Leaf Ju, or at least to two kinds of drugs.

          -  Any unstable cardiovascular, hepatic, renal, blood, endocrine, or other medical
             disease.

          -  Any neurological disease (such as Parkinson's Disease, cerebrovascular accident and
             epilepsy) or cerebral injury (traumatic or disease related).

          -  Had a history or a high risk related disease or medication of seizure disorder, except
             infantile febrile convulsion.

          -  The subject could not take medication or has a disease affecting drug absorption,
             distribution, metabolism and excretion.

          -  Clinically significant electrocardiographic(ECG) abnormalities in screening visit.
             Such as QTc ≥450 ms in male or ≥470 ms in female.

          -  Clinically significant abnormal laboratory values (eg. ALT or AST value above 2 times
             of clinical top-limit; Cr value above normal top-limit; thyroid gland function index
             (≥ 2 items in 5 items) above 1.2 times or below 0.8 times of the normal range, or
             investigator diagnosed with hypothyroidism or hyperthyroidism).

          -  The subject who used at least two different antidepressants with recommended dose and
             adequate duration (maximum dosage by at least 4 weeks according to label) treatment
             still had no respond.

          -  The subject uses antidepressant drug normally before 2 weeks of screening, and stops
             using psychotropic drug before randomization less than 5 half-life period (monoamine
             oxidase inhibitor: at least 2 weeks; fluoxetine: at least 1 month).

          -  The subject received systematic light therapy, laser therapy and acupuncture or other
             Traditional Chinese Medicine, or systemic biofeedback therap within 2 weeks.

          -  The subject received modified ECT, trans-cranial magnetic stimulation (TMS), vagus
             nerve stimulation (VNS) or systematic psychotherapy within 3 months.

          -  Women who were pregnant, breast-feeding, or serum-HCG(+) on screening; or planning to
             become pregnant within 3 months after kick-off of clinical trial.

          -  Education level below junior high school.

          -  The subject has participated in a drug clinical trial within 1 month before screening.

          -  The investigator thinks the subject is unsuitable to enroll in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang LI, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huafang LI, MD. PhD.</last_name>
    <phone>86-21-34773107</phone>
    <email>lhlh_5@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yiming YU, Master</last_name>
    <phone>86-21-34773128</phone>
    <email>mindyfish2001@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anding Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazhou LU, MS</last_name>
      <phone>+86-10-58340310</phone>
      <email>wujinzhizunzhe@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing HuiLongGuan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yajuan NIU, MS</last_name>
      <phone>18601360528</phone>
      <email>niuyajuan@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Sixth Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YI FU, Bachelor</last_name>
      <phone>13683389877</phone>
      <email>fuyi757@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Mental Health Center</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueqin YU, Bachelor</last_name>
      <phone>13983656808</phone>
      <email>243751089@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Brain Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510370</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingbing HUANG, Master</last_name>
      <phone>18922165289</phone>
      <email>hxbing2002@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Hebei Province</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keqing LI, Master</last_name>
      <phone>13703288007</phone>
      <email>like1002@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xinxiang Medical University</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruiling ZHANG, PhD</last_name>
      <phone>18537312153</phone>
      <email>zhangruilingxx@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhumadian mental Hospital</name>
      <address>
        <city>Zhumadian</city>
        <state>Henan</state>
        <zip>463000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongjun CAO, Bachelor</last_name>
      <phone>13938358276</phone>
      <email>Doctorcao139383@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing CHENG, PhD</last_name>
      <phone>18086621321</phone>
      <email>469061443@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi Mental Health Center</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214063</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoqiang WANG, PhD</last_name>
      <phone>13358118972</phone>
      <email>13358118972@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Mental Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kan LI, MS</last_name>
      <phone>13517003676</phone>
      <email>799171881@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brain Hospital of Jilin Province</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <zip>136000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiping TAO, MS</last_name>
      <phone>13843401817</phone>
      <email>taozhiping800@21cn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huafang Li, PH.D</last_name>
      <phone>86-2134773107</phone>
      <email>lhlh_5@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>XI'AN Mental Health Center</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin WU, MS</last_name>
      <phone>13572222831</phone>
      <email>wubing1616@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Kangning Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315201</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zezhong FANG, Master</last_name>
      <phone>13957495039</phone>
      <email>nbfzz888@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression_en.pdf</url>
    <description>EMEA :Guideline on clinical investigation of medicinal products in the treatment of depression.</description>
  </link>
  <link>
    <url>https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM611259.pdf</url>
    <description>FDA.Major Depressive Disorder：Developing Drug for Treatment Guidance for Industry.</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

